Pim Heckman speaks to us about the impact that receiving one of the three 2021 CANTAB Research Grant prizes will have on his research into clearing COVID-19 cognitive brain fog
Jamileth More recently spoke to us about the impact that receiving one of the three 2021 CANTAB Research Grant prizes will have on her research into monitoring protocol of COVID-19 patients survivors of mechanical ventilation.
CANTAB used to assist with identifying patients with mild cognitive impairment and subjective cognit
Dr. Andrea McGrattan, a Research Dietitian and Lecturer in Nutrition and Dietetics, spoke to us about her PhD research at Queen’s University Belfast, using CANTAB cognitive testing within a Mediterranean Diet feasibility study, “THINK-MED”, among people with cognitive impairment.
Find out more about how María Campos Magdaleno, PhD of Universidade de Santiago de Compostela is using CANTAB to investigate cognitive changes in typical and pathological ageing.
At the virtual ADPD 2021 event, Emily Thorp discussed engagement and adherence to remote testing in middle-aged adults at risk of dementia.
Using CANTAB to examine the potential synergistic effects of a combination of omega-3 fatty acids, c
Dr Rebecca Power, Postdoctoral Researcher at the Nutrition Research Centre Ireland, shared the role that CANTAB played in her latest publication: Targeted Nutritional Intervention for Patients with Mild Cognitive Impairment: The Cognitive impAiRmEnt Study (CARES) Trial 1
Dr Simone De Luca recently received the 2020 CANTAB Research Grant primary award for her project: “New ways to assess vascular cognitive impairment and dementia (VCID) in chronic lung disease”. We spoke to her about the impact winning would have on her research.
Older adults shoulder a disproportionate burden of chronic diseases and consumption of prescription drugs. Nevertheless, older adults, especially those aged over 75 years, are chronically under-represented in clinical trials. In this two part series, Dr Kiri Granger explores the risks of under-presentation and outlines guidance for including older adults in clinical trials.
Read on for session two: key design considerations when including elderly patients in clinical trials, with a focus on cognitive assessment.
Cognitive dysfunction in Parkinson’s disease remains a significant, unmet therapeutic need for patients; as such it is vital that there is rigorous research into the topic. Here we will discuss six CANTAB tasks that can address this research gap.
We presented a novel, predictive model of functional decline at CTAD 2018. The model suggests that CANTAB PAL and SWM provide essential screening information when recruiting patients with amnestic mild cognitive impairment into Alzheimer’s disease clinical trials.
At CTAD 2018 we shared our new data on why a Bayesian approach is best to describe normative cognitive performance, especially when making scientifically robust comparisons to neurologically impaired groups.
PhD researcher, Rosalyn Hithersay, spoke to us about her recent publication on which cognitive tests are most sensitive to the early stages of dementia in Down syndrome.
Neural Network classification of longitudinal cognitive data for prediction of individual-level chan
For the first time, Neural Network classifiers have been applied to changes in CANTAB PAL performance between baseline and 10 months to accurately predict the development of MCI at 20 months. Dr Elizabeth Baker, Statistical Scientist at Cambridge Cognition, presented the novel findings at AAIC 2018.
Cognitive dysfunction is a leading cause of disability in multiple sclerosis (MS), yet practical restraints mean it often goes unassessed in routine clinical care. Promising new research, published in Frontiers in Neurology, suggests the Cambridge Neuropsychological Test Automated Battery (CANTAB) may offer a brief and sensitive technological solution.
Comparing visuospatial associative learning for a middle-aged birth cohort and patients with schizop
Visuospatial memory is extremely heterogeneous in schizophrenia. In a large population study, around a fifth of patients with schizophrenia showed similar errors rates to the top 50% of the general population. Conversely, half of the patients sampled showed substantial impairments.
Enriching participant eligibility for clinical trials through pre-screening for cognitive deficit.